Comparative Pharmacology
Head-to-head clinical analysis: ADALAT CC versus ISOPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT CC versus ISOPTIN.
ADALAT CC vs ISOPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.
None Documented
None Documented
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Terminal elimination half-life: 4.5-12 hours (mean 8 hours); increases with hepatic impairment or cirrhosis
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Renal (70% as metabolites, 3-5% unchanged); biliary/fecal (25%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker